Quarterly ResultMay 14, 2026, 04:11 PM
Calidi Biotherapeutics Q1 Net Loss $4.4M; G&A Down $1M
AI Summary
Calidi Biotherapeutics reported a net loss of $4.4 million, or $0.43 per share, for the first quarter of 2026, an improvement from a $5.0 million net loss in the prior year. The company demonstrated a $1.0 million reduction in general and administrative expenses, reflecting a commitment to efficient capital use. Operationally, Calidi presented new data on its CLD-401, RedTail platform, and CLD-501 programs at several major scientific conferences, highlighting profound immune changes and the potential of in situ T-cell engagers. Furthermore, Calidi announced a strategic partnership with TransferAI to streamline the IND submission process for CLD-401, with an IND filing targeted by year-end 2026.
Key Highlights
- Net loss attributable to common stockholders was $4.4 million ($0.43 per share) for Q1 2026, down from $5.0 million ($2.21 per share) in Q1 2025.
- General and administrative expenses decreased by $1.0 million to $1.6 million in Q1 2026 from $2.6 million in Q1 2025.
- Research and development expenses were $2.6 million in Q1 2026, up from $2.4 million in Q1 2025.
- Cash and restricted cash totaled $6.8 million as of March 31, 2026, up from $5.8 million as of December 31, 2025.
- IND filing for CLD-401 is expected by the end of 2026.
- Entered a strategic partnership with TransferAI to enhance efficiencies in the CLD-401 IND submission process.
- Presented new data on CLD-401, RedTail platform, and CLD-501 at AACR, ASGCT, and IOVC conferences.